Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
This synthetic peptide is based on a naturally occurring protective compound found in the stomach
Big Pharma expands its portfolio Earlier this month, Eli Lilly announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes
This early clinical observation, combined with increased accessibility, is what popularized the strategy of Microdosing GLP-1
"As GLP-1 medications become more common, restaurants that adapt to evolving consumer preferences may be better positioned to maintain guest visits and revenue," the report concluded
Notably, the intranasal delivery of drugs, including small molecules, nanoformulations and gene delivery agents, has shown promising outcomes in various rodent models of several neurological pathologies
US$ 21.91
US$ 20.19
US$ 26.93
US$ 21.92
US$ 23.36
